U.S. stock market midday update: YD Bio up 13.13%

U.S. Stock Market Midday Update Stocks with High Trading Volume in the Industry Merus rose 36.30%, with a trading volume of $2.527 billion. Based on recent important news: On September 29, Danish pharmaceutical company Genmab announced the acquisition of Dutch cancer drug developer Merus for approximately $8 billion, causing Merus's stock price to surge. The transaction is expected to be completed in early Q1 2026, and Genmab anticipates a positive impact on its EBITDA by 2029. On September 29, Citigroup lowered the price target for Merus from $101 to $97, reflecting market adjustments to its valuation. On September 29, analysts expect this acquisition to accelerate the company's transformation into a leading global biotechnology firm, providing sustainable growth. The biotechnology sector is experiencing active mergers and acquisitions, with increased market volatility. Forte Pharmaceuticals rose 2.44%. According to recent key news: On September 29, Jefferies raised the price target for Supernus Pharmaceuticals from $45 to $55, driving the stock price up. This move reflects market confidence in the company's future growth potential, leading to an increase in Forte Pharmaceuticals' stock price. On September 28, The Trade Desk's stock price has fallen 60% year-to-date; however, analysts believe this is a temporary setback, and long-term performance remains strong. This market sentiment has influenced the volatility of related stocks. On September 29, Vertex Inc received an upgrade rating from Stephens, with a price target set at $30, indicating market optimism about its future performance, indirectly affecting the market performance of Forte Pharmaceuticals. The U.S. stock market is volatile, with active capital flows. MoonLake Immunotherapeutics fell 89.35%, with a trading volume of $379 million, and the trading volume expanded. According to recent key news: On September 28, MoonLake Immunotherapeutics released the 16-week results of the Vela Phase 3 Hidradenitis Suppurativa project, showing significant improvements in all primary and secondary endpoints for Sonelokimab. However, the results were far below market expectations, leading to a sharp decline in stock price. On September 29, Royal Bank of Canada (RBC) significantly lowered the price target for MoonLake Immunotherapeutics from $67 to $10, further exacerbating negative market sentiment. On September 29, Block & Leviton announced a potential investigation into MoonLake Immunotherapeutics for securities law violations, increasing uncertainty for investors The biotechnology industry has recently experienced significant fluctuations, and risks should be monitored. Stocks ranked at the top of the industry by market capitalization AbbVie rose 0.06%, with a market capitalization of $390 billion. Based on recent important news: On September 29, AbbVie announced the launch of its ovarian cancer drug Elahere in the UK, priced the same as in the US market. This move may enhance the company's influence in international markets and drive up stock prices. Data source: AbbVie company announcement. On September 29, AbbVie began construction of a new active pharmaceutical ingredient manufacturing facility in North Chicago, expected to be fully operational by 2027. This investment plan may enhance the company's production capacity and support stock price increases. Data source: MT Newswires. On September 27, analysts maintained a positive rating on AbbVie, with a target price of $260. Analysts' optimistic expectations may boost market confidence and drive up stock prices. Data source: Wells Fargo analysts. Increased investment in the pharmaceutical industry has strengthened market confidence